Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer biology.

D N Carney1, L De Leij

  • 1Department of Medical Oncology, Mater Misericordiae Hospital, Dublin, Ireland.

Seminars in Oncology
|June 1, 1988
PubMed
Summary

Understanding lung cancer cell heterogeneity is key for improved treatments. Further research into genetic markers and advanced imaging may lead to more targeted therapies and better patient survival rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteosarcoma and second malignant neoplasms: a case series.

Irish journal of medical science·2019
Same author

Is chemotherapy always required for cancer in pregnancy? An observational study.

Irish journal of medical science·2017
Same author

Osteosarcoma in a Patient Receiving Long-Term TNF Inhibitor Therapy.

Irish medical journal·2016
Same author

Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.

Clinical sarcoma research·2015
Same author

Primary bone lymphoma: single institution case series.

Irish journal of medical science·2008
Same author

Predictive testing for BRCA1 and 2 mutations: a male contribution.

Annals of oncology : official journal of the European Society for Medical Oncology·2003

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer biology understanding has advanced, yet treatment outcomes remain stagnant.
  • Lung cancer exhibits significant cellular heterogeneity in growth, biomarkers, and gene expression.
  • Existing treatments do not fully leverage this biological complexity.

Purpose of the Study:

  • To highlight the need for applying knowledge of lung cancer cell heterogeneity in clinical practice.
  • To emphasize the importance of prospectively evaluating the role of heterogeneity in predicting treatment response and survival.
  • To explore novel approaches for drug selection and clinical assessment in lung cancer.

Main Methods:

  • Review of recent advances in lung cancer biology and treatment.
  • Analysis of cell line applications for screening cytotoxic agents.
  • Consideration of magnetic resonance spectroscopy for biological understanding and clinical assessment.
  • Investigation of cytogenetic deletions, specifically on chromosome 3 (3p 14-23), using DNA probes.

Main Results:

  • Heterogeneity in lung cancer cell types requires clinical application for better treatment selection.
  • Prospective evaluation of heterogeneity's role in predicting treatment response and survival is necessary.
  • Cell line screening offers a rational approach for selecting drugs in clinical trials.
  • Magnetic resonance spectroscopy shows potential for understanding lung cancer biology and assessing tumor sensitivity in vivo.
  • A specific cytogenetic deletion (3p 14-23) on chromosome 3 is common across most lung cancer types, supporting a common stem cell hypothesis.

Conclusions:

  • Clinical application of lung cancer cell heterogeneity knowledge is crucial for advancing treatment strategies.
  • Further research into genetic markers and novel imaging techniques like magnetic resonance spectroscopy is warranted.
  • The identification of a common cytogenetic deletion suggests a unifying biological origin for diverse lung cancer histologic types, paving the way for novel therapeutic targets.

Related Experiment Videos